Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages 150-153

  McDermott, Edel ^a   Murphy, Seamus ^a   Keegan, Denise ^a   O'Donoghue, Diarmuid ^a   Mulcahy, Hugh ^a   Doherty, Glen ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Adalimumab; ; Biologics; Inflammatory Bowel Disease; ; Treatment; ; Ulcerative colitis;

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN A; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; REMISSION; SMOKING; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 84872497210     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.016     Document Type: Article

References (14)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998 Jul, 115(1):182-205.
2. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011 Jun 16, 474(7351):307-317.
3. Bosani M., Ardizzone S., Porro G.B. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics Targets Ther 2009, 3:77-97.
4. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 Dec 8, 353(23):2462-2476.
5. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial CLASSIC-I study the efficacy of adalimumab. Gut 2007, 56(9):1232-1239. Sep May.
6. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011 Jun, 60(6):780-787.
7. Wilhelm S.M., McKenney K.A., Rivait K.N., Kale-Pradhan P.B. A review of infliximab use in ulcerative colitis. Clin Ther 2008 Feb, 30(2):223-230.
8. Taxonera C., Estelles J., Fernandez-Blanco I., Merino O., Marin-Jimenez I., Barreiro-de Acosta M., et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011 Feb, 33(3):340-348.
9. Afif W., Leighton J.A., Hanauer S.B., Loftus E.V., Faubion W.A., Pardi D.S., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009 Sep, 15(9):1302-1307.
10. Oussalah A., Laclotte C., Chevaux J.B., Bensenane M., Babouri A., Serre A.A., et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008 Oct 15, 28(8):966-972.
11. Sandborn W.J., van Assche G., Reinisch W., Colombel J.Ä., D'Haens G., Wolf D.C., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012 Feb, 142(2):257-265.e1-3.
12. Gies N., Kroeker K.I., Wong K., Fedorak R.N. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010 Aug, 32(4):522-528.
13. Panccione R., Ghosh S., Middleton S., Marquez J., Khalif I., Flint L., et al. Infliximab, Azathioprine, or Infliximab plus Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial. Gastroenterology 2011, 140(5):S134-S. [Meeting Abstract]. 2011 May.
14. Xie F., Blackhouse G., Assasi N., Gaebel K., Robertson D., Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation: C/E 2009, 7:20.